{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:28:37Z","timestamp":1792718917165,"version":"4.5.0"},"reference-count":43,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"4","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2026,4,21]]},"DOI":"10.1167\/iovs.67.4.49","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:30:49Z","timestamp":1776778249000},"page":"49","source":"Crossref","is-referenced-by-count":2,"title":["Novel Inositol Acyltransferase (Gwt1) Inhibitor for Fungal Keratitis Treatment: Evaluation of In Vitro and In Vivo Efficacy and Safety"],"prefix":"10.1167","volume":"67","author":[{"given":"Lakshminarayanan","family":"Gowtham","sequence":"first","affiliation":[{"name":"Prof Brien Holden Eye Research Centre, LV Prasad Eye Institute, Hyderabad, Telangana, India"},{"name":"Dr. Chigurupati Nageswara Rao Ocular Pharmacology Research Centre, LV Prasad Eye Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yerraguntla","family":"Meghana","sequence":"additional","affiliation":[{"name":"Prof Brien Holden Eye Research Centre, LV Prasad Eye Institute, Hyderabad, Telangana, India"},{"name":"Dr. Chigurupati Nageswara Rao Ocular Pharmacology Research Centre, LV Prasad Eye Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamizhmathy","family":"Mannangatty","sequence":"additional","affiliation":[{"name":"Translational Pharmaceutics Research Laboratory (TPRL), Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Telangana, India"},{"name":"Centre for Ocular Drug Delivery Devices (CODDD), Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Singitam","family":"Vasavi","sequence":"additional","affiliation":[{"name":"Prof Brien Holden Eye Research Centre, LV Prasad Eye Institute, Hyderabad, Telangana, India"},{"name":"Dr. Chigurupati Nageswara Rao Ocular Pharmacology Research Centre, LV Prasad Eye Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayabalan","family":"Nirmal","sequence":"additional","affiliation":[{"name":"Translational Pharmaceutics Research Laboratory (TPRL), Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Telangana, India"},{"name":"Centre for Ocular Drug Delivery Devices (CODDD), Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupesh","family":"Bagga","sequence":"additional","affiliation":[{"name":"Shantilal Shanghvi Cornea Institute, LV Prasad Eye Institute, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Garg","sequence":"additional","affiliation":[{"name":"Shantilal Shanghvi Cornea Institute, LV Prasad Eye Institute, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip Kumar","family":"Mishra","sequence":"additional","affiliation":[{"name":"Ophthalmic Pathology Laboratory, LV Prasad Eye Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanhita","family":"Roy","sequence":"additional","affiliation":[{"name":"Prof Brien Holden Eye Research Centre, LV Prasad Eye Institute, Hyderabad, Telangana, India"},{"name":"Dr. Chigurupati Nageswara Rao Ocular Pharmacology Research Centre, LV Prasad Eye Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/ceo.14113","article-title":"Infectious keratitis: a review","volume":"50","author":"Cabrera-Aguas","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jtos.2021.08.007","article-title":"The epidemiology of infectious keratitis","volume":"28","author":"Stapleton","year":"2023","journal-title":"Ocul Surf"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.4103\/ijo.IJO_3069_21","article-title":"Commentary: tackling the \u201csilent epidemic\u201d","volume":"70","author":"Srinivasan","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/S1473-3099(20)30448-5","article-title":"The global incidence and diagnosis of fungal keratitis","volume":"21","author":"Brown","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3390\/jof7110966","article-title":"Clinical characteristics and outcomes of fungal keratitis in the United Kingdom 2011\u20132020: a 10-year study","volume":"7","author":"Ting","year":"2021","journal-title":"J Fungi"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"698780","DOI":"10.3389\/fcimb.2021.698780","article-title":"Distribution, prevalence, and causative agents of fungal keratitis: a systematic review and meta-analysis (1990 to 2020)","volume":"11","author":"Ahmadikia","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1136\/bjo.2005.076315","article-title":"Characteristic clinical features as an aid to the diagnosis of suppurative keratitis caused by filamentous fungi","volume":"89","author":"Thomas","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1007\/s10792-021-01873-3","article-title":"Update on the management of fungal keratitis","volume":"41","author":"Sha","year":"2021","journal-title":"Int Ophthalmol"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jtos.2021.12.001","article-title":"Fungal keratitis: a review of clinical presentations, treatment strategies, and outcomes","volume":"24","author":"Sharma","year":"2022","journal-title":"Ocul Surf"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s00203-023-03536-6","article-title":"Eye fungal infections: a mini review","volume":"205","author":"Reginatto","year":"2023","journal-title":"Arch Microbiol"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1001\/archophthalmol.2011.315","article-title":"Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT)","volume":"130","author":"Srinivasan","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1001\/jamaophthalmol.2013.1497","article-title":"The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole","volume":"131","author":"Prajna","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/jof6040239","article-title":"Fosmanogepix: a review of the first-in-class broad-spectrum agent for the treatment of invasive fungal infections","volume":"6","author":"Shaw","year":"2020","journal-title":"J Fungi"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"e02343","DOI":"10.1128\/AAC.02343-20","article-title":"Manogepix, the active moiety of the investigational agent fosmanogepix, demonstrates in vitro activity against members of the Fusarium oxysporum and Fusarium solani species complexes","volume":"65","author":"Badali","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jgar.2021.04.012","article-title":"Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018\u20132019)","volume":"26","author":"Pfaller","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"bib17","first-page":"e01717","article-title":"GERMS-SA. In vitro antifungal activity of manogepix and other antifungal agents against South African Candida auris isolates from bloodstream infections","volume":"10","author":"Mapangha","year":"2022","journal-title":"Microbiol Spectr"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1136\/bjo.84.1.54","article-title":"Corneal ulceration in the elderly in Hyderabad, south India","volume":"84","author":"Kunimoto","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/ICL.0000000000000689","article-title":"Rabbit fungal keratitis model of Fusarium solani tested against three commercially available antifungal drugs","volume":"46","author":"Aung","year":"2020","journal-title":"Eye Contact Lens"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1021\/cb300235m","article-title":"Inhibiting GPI anchor biosynthesis in fungi stresses the endoplasmic reticulum and enhances immunogenicity","volume":"7","author":"McLellan","year":"2012","journal-title":"ACS Chem Biol"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"126713","DOI":"10.1016\/j.bmcl.2019.126713","article-title":"Synthesis of analogs of the Gwt1 inhibitor manogepix (APX001A) and in vitro evaluation against Cryptococcus spp","volume":"29","author":"Trzoss","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"e01715","DOI":"10.1128\/AAC.01715-18","article-title":"APX001 and other Gwt1 inhibitor prodrugs are effective in experimental Coccidioides immitis pneumonia","volume":"63","author":"Viriyakosol","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"e00523","DOI":"10.1128\/AAC.00523-18","article-title":"In vitro and in vivo evaluation of APX001A\/APX001 and other Gwt1 inhibitors against Cryptococcus","volume":"62","author":"Shaw","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"bib27","doi-asserted-by":"crossref","first-page":"e00840","DOI":"10.1128\/AAC.00840-19","article-title":"In vitro activity of APX001A (manogepix) and comparator agents against 1,706 fungal isolates collected during an international surveillance program in 2017","volume":"63","author":"Pfaller","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"S646","DOI":"10.1093\/ofid\/ofaa439.1444","article-title":"Activity of manogepix (APX001A) against 2,669 fungal isolates from the SENTRY surveillance program (2018\u20132019) stratified by infection type","volume":"7","author":"Huband","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 2","key":"bib29","doi-asserted-by":"crossref","first-page":"ofac492.1665","DOI":"10.1093\/ofid\/ofac492.1665","article-title":"In vitro activity of manogepix against 2,810 fungal isolates from the SENTRY surveillance program (2020\u20132021) stratified by infection type","volume":"9","author":"Huband","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"e01028","DOI":"10.1128\/aac.01028-22","article-title":"Activities of manogepix and comparators against 1,435 recent fungal isolates collected during an international surveillance program (2020)","volume":"66","author":"Pfaller","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"bib31","doi-asserted-by":"crossref","first-page":"e00730","DOI":"10.1128\/AAC.00730-20","article-title":"In vitro activity of manogepix (APX001A) and comparators against contemporary molds: MEC comparison and preliminary experience with colorimetric MIC determination","volume":"64","author":"J\u00f8rgensen","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"bib32","first-page":"1473","article-title":"Comparative evaluation of antifungal susceptibility profiles of ocular Fusarium isolates from different geographical regions","volume":"53","author":"Sharma","year":"2015","journal-title":"J Clin Microbiol"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1093\/jac\/dku259","article-title":"Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania","volume":"69","author":"Chowdhary","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous emergence of multidrug-resistant Candida auris on three continents confirmed by whole-genome sequencing and epidemiological analyses","volume":"64","author":"Lockhart","year":"2017","journal-title":"Clin Infect Dis"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/jof8101102","article-title":"Calcineurin inhibitors synergize with manogepix to kill diverse human fungal pathogens","volume":"8","author":"Liston","year":"2022","journal-title":"J Fungi"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"e01645","DOI":"10.1128\/aac.01645-22","article-title":"Heightened efficacy of anidulafungin when used in combination with manogepix or 5-flucytosine against Candida auris in vitro","volume":"67","author":"John","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"e00137","DOI":"10.1128\/aac.00137-25","article-title":"Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains","volume":"69","author":"Ceballos-Garzon","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"e01623","DOI":"10.1128\/aac.01623-22","article-title":"Safety and pharmacokinetics of intravenous and oral fosmanogepix, a first-in-class antifungal agent, in healthy volunteers","volume":"67","author":"Hodges","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"bib39","doi-asserted-by":"crossref","first-page":"e01455","DOI":"10.1128\/aac.01455-23","article-title":"Pharmacokinetics, safety, and tolerability of fosmanogepix IV-to-oral switch and multiple IV doses in healthy participants","volume":"68","author":"Hodges","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"bib40","doi-asserted-by":"crossref","first-page":"e01120","DOI":"10.1128\/AAC.01120-19","article-title":"Efficacy of delayed therapy with fosmanogepix (APX001) in a murine model of Candida auris invasive candidiasis","volume":"63","author":"Wiederhold","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"e01795","DOI":"10.1128\/AAC.01795-20","article-title":"Efficacy and pharmacokinetics of fosmanogepix (APX001) in the treatment of Candida endophthalmitis and hematogenous meningoencephalitis in nonneutropenic rabbits","volume":"65","author":"Petraitiene","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"e01735","DOI":"10.1128\/AAC.01735-19","article-title":"Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis","volume":"64","author":"Alkhazraji","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"e00380","DOI":"10.1128\/aac.00380-22","article-title":"Combination treatment of fosmanogepix and liposomal amphotericin B is superior to monotherapy in treating experimental invasive mold infections","volume":"66","author":"Gebremariam","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"bib16","article-title":"A phase 3 efficacy and safety study of fosmanogepix for the treatment of adult patients with invasive mold infections"},{"key":"bib19","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard. 4th ed. CLSI document M27-A4","author":"Clinical and Laboratory Standards Institute","year":"2017"},{"key":"bib20","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard\u20143rd ed. CLSI document M38","author":"Clinical and Laboratory Standards Institute","year":"2017"},{"key":"bib22","volume-title":"WHO fungal priority pathogens list to guide research, development and public health action","author":"World Health Organization","year":"2022"}],"container-title":["Investigative Ophthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?doi=10.1167\/iovs.67.4.49","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:32:20Z","timestamp":1791927140000},"score":1,"resource":{"primary":{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?doi=10.1167\/iovs.67.4.49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.67.4.49","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}